Renin Profiling in Selection of Initial Antihypertensive Drug
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
olmesartan, hydrochlorothiazide, amlodipine
hydrochlorothiazide (HCTZ) or olmesartan
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Males and females, 40 to 85 years of age
- Sustained systolic blood pressure between 140-180 mm Hg
- Free of antihypertensive therapy at randomization for at least 4 weeks
Exclusion criteria:
- Ages <40, or >85 years
- Systolic blood pressure >180 mm Hg
- Blood pressure >180/105 mm Hg during the washout period
- Require antihypertensive agents for non-blood pressure indications
- Taking clonidine
- On a beta-blocker drug and have known or suspected coronary artery disease
- Documented history of a heart attack, new onset of chest pain, or a coronary revascularization procedure within the past year, congestive heart failure
- Serious intercurrent illness
- An active ulcer
- Have certain abnormal laboratory tests (elevated serum creatinine >1.5 mg/dl, transaminase > 2 times upper limit of normal or active liver disease),
- Hypersensitivity, allergy or have an intolerance to angiotensin II receptor blockers (olmesartan), hydrochlorothiazide or amlodipine
- Mentally or legally unable to participate
- Have or are currently abusing alcohol, have abused drugs within the past 2 years
- Have been in another drug study in the past month.
Sites / Locations
- Lincoln Medical and Mental Health Center
- Albert Einstein College of Medicine - GCRC
- Jacobi Medical Center
- Bronx Nephrology Hypertension, PC
- Ralph Yung, MD
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
HCTZ , ARB
Conventional antihypertensive therapy
Arm Description
Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
Outcomes
Primary Outcome Measures
Percent of patients with BP <140/90 mmHg and on monotherapy at the 5th visit.
Secondary Outcome Measures
Will include change in blood pressure, percent of patients with blood pressure <140/mmHg, total number of classes of antihypertensive agents taken, adverse events and discontinuation of therapy.
In addition, we will be able to determine the reproducibility of PRA determination in this clinical setting. Finally, it will be possible to demonstrate the value of "in-treatment" PRA as a guide to treatment modification.
Full Information
NCT ID
NCT00834600
First Posted
January 30, 2009
Last Updated
April 18, 2012
Sponsor
The Louis & Rachel Rudin Foundation
Collaborators
Daiichi Sankyo, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00834600
Brief Title
Renin Profiling in Selection of Initial Antihypertensive Drug
Official Title
A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug
Study Type
Interventional
2. Study Status
Record Verification Date
October 2010
Overall Recruitment Status
Completed
Study Start Date
December 2005 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
October 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Louis & Rachel Rudin Foundation
Collaborators
Daiichi Sankyo, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this research study is to determine whether a simple blood test measuring a hormone called renin can better determine which first drug would be most effective in controlling blood pressure, in comparison with the more traditional approach recommended by JNC7 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure).
Detailed Description
Hypothesis: That antihypertensive drug selection guided by activity of the renin angiotensin system will be superior to the strategy advocated in JNC 7 in achieving blood pressure control on monotherapy.
Background: the National Heart, Lung, and Blood Institute, through the Joint National Committee on the Detection, Treatment and Control of Hypertension (JNC 7) has recommended that most hypertensive patients begin therapy with a diuretic and sequentially add other classes of drugs until blood pressure is controlled. This approach appears to assume homogeneity in the mechanism by which BP is controlled in different patients. When this standardized strategy has been rigidly applied in Clinical Trials, a majority of patients generally require 2 or more agents to achieve blood pressure control.
The pioneering work of Laragh, Sealey and their colleagues, widely confirmed by others, suggests instead that heterogeneity, in fact, characterizes patterns of blood pressure control in populations. This heterogeneity can be exposed through assessment of the activity of the renin angiotensin system (RAS). Specifically, volume and vasoconstriction determine blood pressure control. Patients in whom volume predominates have suppressed RAS, and, conversely, those in whom vasoconstriction predominates will have an activated RAS. This can be simply and accurately determined by estimation of plasma renin activity (PRA).
It has been demonstrated that volume and vasoconstriction dependent hypertensive patients respond best to different drugs. By exploitation of the RAS it is possible to provide rational therapy to each patients according to the mechanism by which blood pressure is controlled. The result is that appropriate therapy can be both more effective and more efficient. A specific system the Laragh Method has been designed to translate this physiologically based paradigm into a practical scheme or patient management.
The purpose of this trial is to determine whether the Laragh Method will lead to better and more efficient blood pressure control in a general population of hypertensive patients than does the existing treatment strategy. The measure by which this hypothesis will be tested is percentage of hypertensive patients achieving blood pressure control on monotherapy.
The significance of this trial is enormous for both individuals and society. Some 50 million Americans have hypertension and more than 25 million are currently in treatment. If the Laragh Method leads to more parsimonious and effective care, it will mean literally millions of individual patients will be spared the burden of unnecessary polypharmacy. Moreover, the strain on health care costs associated with antihypertensive therapy will be redu
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
185 (Actual)
8. Arms, Groups, and Interventions
Arm Title
HCTZ , ARB
Arm Type
Experimental
Arm Description
Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
Arm Title
Conventional antihypertensive therapy
Arm Type
Active Comparator
Arm Description
All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
Intervention Type
Drug
Intervention Name(s)
olmesartan, hydrochlorothiazide, amlodipine
Other Intervention Name(s)
Renin guided selection of treatment
Intervention Description
hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
Intervention Type
Drug
Intervention Name(s)
hydrochlorothiazide (HCTZ) or olmesartan
Other Intervention Name(s)
Standard Therapy
Intervention Description
HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
Primary Outcome Measure Information:
Title
Percent of patients with BP <140/90 mmHg and on monotherapy at the 5th visit.
Time Frame
3-4 months
Secondary Outcome Measure Information:
Title
Will include change in blood pressure, percent of patients with blood pressure <140/mmHg, total number of classes of antihypertensive agents taken, adverse events and discontinuation of therapy.
Time Frame
3-4 months
Title
In addition, we will be able to determine the reproducibility of PRA determination in this clinical setting. Finally, it will be possible to demonstrate the value of "in-treatment" PRA as a guide to treatment modification.
Time Frame
3-4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and females, 40 to 85 years of age
Sustained systolic blood pressure between 140-180 mm Hg
Free of antihypertensive therapy at randomization for at least 4 weeks
Exclusion criteria:
Ages <40, or >85 years
Systolic blood pressure >180 mm Hg
Blood pressure >180/105 mm Hg during the washout period
Require antihypertensive agents for non-blood pressure indications
Taking clonidine
On a beta-blocker drug and have known or suspected coronary artery disease
Documented history of a heart attack, new onset of chest pain, or a coronary revascularization procedure within the past year, congestive heart failure
Serious intercurrent illness
An active ulcer
Have certain abnormal laboratory tests (elevated serum creatinine >1.5 mg/dl, transaminase > 2 times upper limit of normal or active liver disease),
Hypersensitivity, allergy or have an intolerance to angiotensin II receptor blockers (olmesartan), hydrochlorothiazide or amlodipine
Mentally or legally unable to participate
Have or are currently abusing alcohol, have abused drugs within the past 2 years
Have been in another drug study in the past month.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael H Alderman, M.D.
Organizational Affiliation
Albert Einstein College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lincoln Medical and Mental Health Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10451
Country
United States
Facility Name
Albert Einstein College of Medicine - GCRC
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Jacobi Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Facility Name
Bronx Nephrology Hypertension, PC
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
Ralph Yung, MD
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
14656957
Citation
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2. Epub 2003 Dec 1.
Results Reference
background
Citation
Laragh JH: Laragh's Lessons in Renin System Pathophysiology for Treating Hypertension and its Fatal Cardiovascular Consequences. Elsevier Science Inc.,2002,N.Y.
Results Reference
background
Citation
Laragh JH, Sealey JE. Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity, and find the best-fit drug regimen. Chapter 107, In: Hypertension:Pathophysiology Diagnosis and Management, 2nd Edition, Edited by JH Laragh and BM Brunner. Raven Press,Ltd.,New York 1995.
Results Reference
background
PubMed Identifier
6120769
Citation
Sealey JE. Measurement of the hormones of the renin system in hypertensive patients. Clin Biochem. 1981 Oct;14(5):273-81. doi: 10.1016/s0009-9120(81)91000-6. No abstract available.
Results Reference
background
Learn more about this trial
Renin Profiling in Selection of Initial Antihypertensive Drug
We'll reach out to this number within 24 hrs